This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
by Ahan Chakraborty
Black Diamond's May 2026 silevertinib update showed steady NSCLC response rates, CNS activity and dose progress, but durability data remain early.
AZNNegative Net Change JNJPositive Net Change BDTXNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Novo Nordisk vs. Amgen: Which Pharma Stock Is the Better Buy?
by Ahan Chakraborty
NVO and AMGN square off as GLP-1 leadership, pipeline depth and diversification shape a compelling healthcare stock comparison.
NVONegative Net Change LLYPositive Net Change AMGNNegative Net Change
biotechnology biotechs medical pharmaceuticals
Dyne Therapeutics Stock Gains 4.5% After BLA Filing for DMD Therapy
by Zacks Equity Research
DYN shares jump after the company files a BLA with the FDA for z-rostudirsen in Duchenne muscular dystrophy.
DYNPositive Net Change LQDAPositive Net Change IMCRPositive Net Change INDVNegative Net Change
biotechs
FDA Extends Review Time for AZN's Camizestrant Combo in Breast Cancer
by Zacks Equity Research
AstraZeneca faces a longer FDA review for camizestrant combo in a certain type of first-line breast cancer after regulators request additional data.
AZNNegative Net Change IMCRPositive Net Change DSGNNegative Net Change JSPRPositive Net Change
biotechs medical
Can Asceniv Help ADMA Navigate the Current IG Market Challenges?
by Ekta Bagri
ADMA faces IG pricing pressure and reduced 2026 guidance, but Asceniv demand remains strong amid resilient patient utilization.
GRFSNegative Net Change ADMANegative Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
How Agenus' Pipeline Progress Unlock Its Next Growth Phase
by Zacks Equity Research
AGEN advances BOT/BAL into phase III for MSS colorectal cancer as survival data and global access efforts shape its next growth phase.
BMYPositive Net Change MRKNegative Net Change AGENPositive Net Change
biotechs medical pharmaceuticals
Here's Why You Should Add JANX Stock to Your Portfolio Now
by Zacks Equity Research
Janux Therapeutics advances multiple oncology and immune therapy programs with key clinical updates, new studies and expanded partnerships with BMY and MRK.
BMYPositive Net Change MRKNegative Net Change JANXPositive Net Change
biotechs
Can EU Label Expansions of NVO's GLP-1 Drugs Spur Sales Growth?
by Ahan Chakraborty
Novo Nordisk's EU label expansions may widen semaglutide use and boost volumes, but pricing pressure and Lilly rivalry can limit recovery.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
AMGN Stock Down 13% in 3 Months: Buy the Dip or Book Profits?
by Kinjel Shah
Amgen faces LOE headwinds and pricing pressure, yet key growth drugs and biosimilars continue gaining traction.
NVONegative Net Change LLYPositive Net Change AMGNNegative Net Change
biotechs
MRK Stock Gains After CHMP Backs Keytruda Combo for Bladder Cancer
by Zacks Equity Research
Merck jumps after CHMP backs Keytruda plus Padcev for certain bladder cancer patients, a combo with the potential to expand treatment options.
PFENegative Net Change MRKNegative Net Change ALPMYPositive Net Change
biotechs medical pharmaceuticals